Project neuroARTEMIS for HIV, Stimulant Use, and Depression
This study, Project neuroARTEMIS, aims to understand how stress affects the brain and immune system in people living with HIV who also use stimulants and experience depression. Researchers hope to find better ways to treat depression and stimulant use. You might be eligible if you are 18-59 years old, have HIV, take daily antiretroviral therapy (ART) medication, use stimulants weekly, and speak English. The study tests an intervention called ARTEMIS, which teaches positive coping skills, and also provides contingency management (CM) to help with ART adherence. Success will be measured by changes in brain activity and connectivity after 3 months. The current recruitment status is unclear.
- Study design
- This interventional study plans to enroll 189 participants. Participants will be randomly assigned to either receive the ARTEMIS intervention or be in a waitlist control group.
- What's involved
- Participants will complete a baseline assessment including surveys, biological samples, and an MRI brain scan. Those in the ARTEMIS group will have 5 Zoom sessions over 3 months. All participants will use a mobile app to upload videos for ART adherence.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will have follow-up assessments at 3 and 6 months after the start of the study. Waitlist control participants will be offered the ARTEMIS intervention after a 6-month delay.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Project neuroARTEMIS
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Christina S Meade, PhD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences
- Adam W Carrico, PhD · PRINCIPAL_INVESTIGATOR · Florida International University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Neural Functional ConnectivityMonth 3
Functional connectivity (FC) will be derived from the the resting-state functional MRI data. Using a theory-driven, seed-based approach, the 4D time series \[average blood oxygenation level dependent (BOLD) signal across voxels\] will be extracted from a priori seeds in the reward network (i.e., nucleus accumbens, subgenual anterior cingulate cortex, medial orbitofrontal cortex). Normalized Z-scores will be calculated for FC between regions of interest. These analyses will control for baseline FC.
- Neural ActivationMonth 3
The Monetary Incentive Delay Task will be used to probe neural activation to reward processing, using an event-level design. Blood oxygenation level dependent (BOLD) activation will be modeled as a canonical hemodynamic response function specified at stimulus onset. Event epochs that are time locked to the onset of each trial will be extracted from the overall time series. Random-effects general linear model will be used to calculate statistical parametric maps reflecting the probability that a voxel is activated as a function of the experimental task. The primary analysis will focus on nucleus accumbens and ventromedial prefrontal cortex activity as regions of interest (ROI). Mean beta values will be averaged across all voxels in each ROI. These analyses will control for baseline activation levels.